SEC Form 4 · accession 0001209191-16-132661
Orexigen Therapeutics, Inc. · OREXQ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Patrick J Mahaffy
Director
Period of report
Jul 12, 2016
Accepted (ET)
Jul 14, 2016 · 1:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001382911
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF2,F1 | $4.02 | Jul 12, 2016 | A | 15,000 | A | — | Jul 11, 2026 | Common Stock | 15,000 | 15,000 | D |
Explanation of responses
- F1The shares of stock subject to the option (rounded down to the next whole number of shares) shall vest in equal monthly installments over 12 months following 07/08/2016, subject to the Director's continuing service on the Board through each such date; provided, that if a Change in Control (as defined in the Plan) occurs, such option, to the extent unvested, shall become fully vested immediately prior to such Change in Control, subject to the Director's continuing service on the Board, as set forth in the applicable stock option grant notice and stock option agreement for such Director.
- F2Not Applicable